HFSA announces late-breaking research for 2024 annual meeting
The Heart Failure Society of America (HFSA) has shared the full program of late-breaking clinical research scheduled for HFSA 2024, the group’s annual meeting. While some presentations will take place on the HFSA plenary session stage, others will be delivered via Rapid Fire sessions designed to be “fast-paced and brief.”
HFSA 2024 is scheduled for Sept. 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta.
Sept. 29 | Plenary Session Stage | 9 a.m. – 10:30 a.m.
- STEP-HFpEF
- Efficacy Of Semaglutide In Patients With Obesity And HFpEF According To Frailty Status: A Pooled Analysis From The STEP-HFpEF Program
- Effects Of Semaglutide In Patients With Obesity-related Heart Failure With Preserved Ejection Fraction According To The Exercise Function At Baseline: Insights From The STEP-HFpEF Program
- FINEARTS-HF
- Efficacy And Safety Of Finerenone In Patients With Heart Failure And Mildly Reduced Or Preserved Ejection Fraction And A Recent Worsening Heart Failure Event: The FINEARTS-HF Trial
- Efficacy And Safety Of Finerenone Across The Ejection Fraction Spectrum In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
- HELIOS-B
- Exploratory Analyses From HELIOS-B, A Phase 3 Study Of Vutisiran In Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Another title to be announced.
Sept. 30 | Plenary Session Stage | 9 a.m. – 10:30 a.m.
- SEQUOIA-HCM
- Global Clinical Impact Of Aficamten In Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
- EMBARK-HFpEF
- Myosin Inhibition In Heart Failure With Preserved Ejection Fraction: Primary Results Of The EMBARK HFpEF Trial
- ARIES-HM3
- Impact Of Pharmacological Therapy On Hemocompatibility Following Left Ventricular Assist Device Implantation: An Analysis From The ARIES-HM3 Trial
- EXPANDed
- Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair With The MitraClip System
- HuMAIN-HFpEF
- A Novel Controlled Metabolic Accelerator For The Treatment Of Obesity-related Heart Failure With Preserved Ejection Fraction: HuMAIN-HFpEF Trial
Sept. 28 | Rapid Fire Session 1: Not Just Plug and Play: Devices and Health Technology in Heart Failure | 4 p.m. - 5 p.m.
- Interstitial Decongestion with Device-Based Thoracic Duct Decompression in Acute Decompensated Heart Failure Patients
- RECOVER-HF Pilot Study: Synchronized Diaphragmatic Stimulation For HFrEF Therapy
- PROACTIVE HF: 12-Month Results
- Safety And Technical Endpoints And Accurate Volume Assessment Using An Implanted Inferior Vena Cava Sensor
- Electronic Alerts To Improve Heart Failure Therapy Throughout An Integrated Health System: Prompt-HF Inova
- Effect Of Finerenone On Kansas City Cardiomyopathy Questionnaire (KCCQ) Score In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
Sept. 29 | Rapid Fire Session 2: Birds of a Feather: Cardio-kidney-metabolism and HFpEF | 5:15 p.m. - 6:15 p.m.
- Efficacy And Safety Of Finerenone According To Age In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
- The Effects Of Burst Steroid Therapy On Short Term Decongestion In Acute Heart Failure: The CORTAHF Randomized, Open-Label, Pilot Trial
- Effects Of Exogenous Ketone Therapy On Exercise Capacity In Heart Failure With Preserved Ejection Fraction: KETO-HFpEF
- Metabolic Responses To Exercise Following Weight Loss Surgery: WTLOSS-EX Trial
- Efficacy Of A Home-Based M-Health Cardiac Rehabilitation Program Among Older Adults With Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Controlled Trial
- Understanding The Real-World Management Of Patients With Heart Failure At Risk For Hyperkalemia: Initial Results From The CARE-HK In Heart Failure (HF) Registry
- Unsaturated Fatty Acids To Improve Cardiorespiratory Fitness In Obesity-Related Heart Failure With Preserved Ejection Fraction: The UFA-Preserved2 Randomized Controlled Cross-over Study
Sept. 30 | Rapid Fire Session 3: See One, Do One: Emerging Therapeutic Strategies in Cardiomyopathies and Heart Failure | 10:45 a.m. - 11:45 a.m.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study On The Safety And Efficacy Of Istaroxime For Pre-Cardiogenic Shock
- First In Human Gene Therapy For The Cardiomyopathy Of Friedreich Ataxia
- Differences In Self -care Of Heart Failure Index Among Patients With Heart Failure With And Without Symptom Coaching Messages: A Pilot Clinical Trial Study
- Efficacy Of Single Dose Furoscix vs. Home Dose Furosemide In Patients Recently Hospitalized For Heart Failure Across Diuretic Resistance Strata: A Pilot Randomized Controlled Trial
- AuXillary OUTpatient Management Of VAD BLEEDing: The AXOUT VAD BLEED Pilot Study
- Pulmonary Artery Pressures In Relation To Serial Cardiovascular Blood Biomarkers In Chronic Heart Failure Patients
- American Registry Of Ambulatory Or Acute Decompensated Heart Failure (AMERICCAASS): Current Results
Click here for additional information about the upcoming HFSA annual meeting. More HFSA-related content is available here.
Michael Walter, Managing Editor
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.